Raymond James Financial
ELDN icon

Raymond James Financial’s Eledon Pharmaceuticals ELDN Stock Holding History

Raymond James Financial’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43K Buy
13,977
+3,377
+32% +$7.95K ﹤0.01% 5136
2025
Q4 		$16K Buy
+10,600
New +$25.2K ﹤0.01% 5107
2025
Q3 		– Sell
-600
Closed -$1.63K – 5496
2025
Q2 		$1.63K Buy
+600
New +$1.8K ﹤0.01% 6458

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Raymond James Financial's ELDN Position: Q1 2026 in Review

Raymond James Financial increased its Eledon Pharmaceuticals (ELDN) stake by 32% in Q1 2026, buying an estimated $7.95K and bringing the position to 13,977 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #5136.

Raymond James Financial first reported a position in ELDN in Q2 2025 and has held it in 3 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Raymond James Financial held 13,977 shares of Eledon Pharmaceuticals worth $43K as of Q1 2026.
  • Raymond James Financial bought 3,377 Eledon Pharmaceuticals shares in Q1 2026, an estimated $7.95K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5136 holding.
  • Raymond James Financial first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.